Strontium ranelate: a new paradigm in the treatment of osteoporosis.
REGINSTER, Jean-Yves ; LECART, Marie-Paule ; DEROISY, Rita et al
in Expert Opinion on Investigational Drugs (2004), 13(7), 857-64
In vitro, strontium ranelate increases collagen and non-collagenic protein synthesis by mature osteoblast-enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug ... [more ▼]
In vitro, strontium ranelate increases collagen and non-collagenic protein synthesis by mature osteoblast-enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated osteoclast, a preincubation of bone slices with strontium ranelate induced a dose-dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. The drug was administered in 160 early postmenopausal women, in a 24-month, double-blind, placebo-controlled, prospective randomised study. At the conclusion of the study, the percentage variation of lumbar bone mineral density (BMD) from baseline was significantly different in the group receiving strontium ranelate 1000 mg/day as compared with placebo (+5.53 versus -0.75%, respectively). Increase in total hip and neck BMD averages were 3.2 and 2.5%, respectively. The effect of strontium ranelate in postmenopausal women with established osteoporosis was assessed during a multinational, prospective, double-blind, randomised, placebo-controlled trial. Strontium ranelate (500, 1000, 2000 mg/day) or placebo were given to 353 Caucasian women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study, the annual increase in lumbar BMD of the group receiving strontium ranelate 2000 mg was 7.3% (p < 0.001). A significant increase in bone alkaline phophatase (p = 0.002) over a 6-month period and a significant decrease in N-telopeptide crosslinks (p = 0.004) throughout the 2-year period were seen in the group receiving 2000 mg of strontium ranelate. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. Bone histomorphometry showed no mineralisation defects. The primary analysis of the SOTI study, evaluating the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patients experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture in the group treated with strontium ranelate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture was also demonstrated in the patients treated for > or = 18 months. [less ▲]Detailed reference viewed: 11 (6 ULg)
Traitement structurel de l'arthrose : le point en 2004
Reginster, Jean-Yves ; LECART, Marie-Paule ; SARLET, Nathalie
in Ortho-Rhumato (2004), 2(3), 52-54Detailed reference viewed: 4 (2 ULg)
Treatment of osteoporosis with biphosphonates - Do compliance and persistence matter ?
Reginster, Jean-Yves ; LECART, Marie-Paule
in Business briefing : Long-term Healthcare (2004), 5Detailed reference viewed: 7 (4 ULg)
Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis
Reginster, Jean-Yves ; Bruyère, Olivier ; Lecart, Marie-Paule et al
in Current Opinion in Rheumatology (2003), 15
Purpose of review Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may ... [more ▼]
Purpose of review Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may delay the structural progression of osteoarthritis. Recent findings The most compelling evidence of a potential for inhibiting the structural progression of osteoarthritis has been obtained with glucosamine sulfate, whereas preliminary results obtained in patients with osteoarthritis of the hands also suggest that chondroitin sulfate could be used in the same indication. At any rate, these two compounds have clearly demonstrated a symptomatic action, mainly in osteoarthritis of the lower limbs. Patients with the less severe radiographic osteoarthritis will experience, in the long run, the most dramatic disease progression in terms of joint space narrowing. Such patients may be particularly responsive to structure-modifying drugs. Summary Glucosamine sulfate has demonstrated its ability to reduce the progression of osteoarthritis in the lower limbs. The preliminary results obtained in the hands suggest that chondroitin sulfate could also be of interest in this indication. An important issue is that all the conclusive studies with such chemical entities resulted from the use of prescription medicines, not over-the-counter pills or food supplements. [less ▲]Detailed reference viewed: 19 (5 ULg)
Prevention de la fracture de la hanche chez le sujet age: ou en sommes-nous en 2003?
Reginster, Jean-Yves ; Lecart, Marie-Paule ; Sarlet, Nathalie et al
in Revue Médicale de Liège (2003), 58(4), 183-90
Osteoporosis in very elderly subjects is now considered, in most developed and several developing countries as a major social, clinical and financial burden. While many compounds have been investigated in ... [more ▼]
Osteoporosis in very elderly subjects is now considered, in most developed and several developing countries as a major social, clinical and financial burden. While many compounds have been investigated in the prevention or treatment of spinal fractures, few of them have unequivocally demonstrated their ability to reduce the risk of non vertebral and more specifically hip fractures in the very elderly. This situation may seem highly paradoxical since hip fractures are unanimously considered to be the most dramatic and disabling consequence of osteoporosis. The present article reviews the current evidence available to justify anti-osteoporotic medications to be recommended to very elderly subjects, in the perspective of reducing their risk of appendicular fractures. [less ▲]Detailed reference viewed: 26 (4 ULg)
Prévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard.
Reginster, Jean-Yves ; DEROISY, Rita ; LECART, Marie-Paule et al
in Santé Publique : Revue Multidisciplinaire pour la Recherche et l'Action (1996), 2Detailed reference viewed: 4 (2 ULg)
Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate
Reginster, Jean-Yves ; Lecart, Marie-Paule ; Deroisy, Rita et al
in Annals of the Rheumatic Diseases (1993), 52(1), 54-7
Chloro-4-phenyl thiomethylene bisphosphonate (tiludronate) is a new drug which can be used as an inhibitor of bone resorption. As it remains in bone for a long time, and as mineralisation defects have ... [more ▼]
Chloro-4-phenyl thiomethylene bisphosphonate (tiludronate) is a new drug which can be used as an inhibitor of bone resorption. As it remains in bone for a long time, and as mineralisation defects have only been seen at doses much higher than those required to decrease osteoclastic activity, it could be given at high doses over a short period of time. Eighteen patients with Paget's disease of bone were randomly allocated to three therapeutic groups receiving respectively 600, 800, and 1200 mg/day tiludronate for five days. Serum alkaline phosphatase activity and the urinary hydroxyproline/creatinine ratio were quickly and drastically reduced in all three groups. A significant reduction of serum alkaline phosphatases and the hydroxyproline/creatinine ratio was still present six months after the five day therapeutic course, reflecting a sustained activity of tiludronate even after stopping treatment. Dose dependent short and long term reductions of bone turnover rate were observed. Biochemical assessment of haematological, renal, or hepatic tolerance did not show any toxicity of tiludronate. Fifty per cent of patients treated by a dose of 1200 mg/day reported gastrointestinal disturbances, however, making this dosage unsuitable for clinical practice. [less ▲]Detailed reference viewed: 15 (1 ULg)
Relationship between Whole Plasma Calcitonin Levels, Calcitonin Secretory Capacity, and Plasma Levels of Estrone in Healthy Women and Postmenopausal Osteoporotics
Reginster, Jean-Yves ; Deroisy, Rita ; Albert, Adelin et al
in Journal of Clinical Investigation (1989), 83(3), 1073-7
The exact role of calcitonin (CT) in the pathogenesis of postmenopausal osteoporosis remains unknown. Whole plasma calcitonin (iCT) basal levels, metabolic clearance rate (MCR), and production rate (PR ... [more ▼]
The exact role of calcitonin (CT) in the pathogenesis of postmenopausal osteoporosis remains unknown. Whole plasma calcitonin (iCT) basal levels, metabolic clearance rate (MCR), and production rate (PR) of CT were measured in 9 premenopausal and 16 postmenopausal women, including 11 osteoporotics (OP). Basal iCT levels were statistically lower in postmenopausal women than in the premenopausal group (P less than 0.01) and strongly correlated (r = 0.72; P less than 0.001) with estrone circulating levels (E1). MCR were similar in all groups. PR were similar in eugonadal women between 22 (mean +/- SD = 30.9 +/- 9.9 micrograms/d) and 37 yr (mean +/- SD = 25.5 +/- 11.1 micrograms/d) premenopausal women. In healthy postmenopausal women PR were reduced, but not significantly (mean +/- SD = 19.5 +/- 6.95 micrograms/d), whereas osteoporotic patients presented a highly significant reduction of CT PR (mean +/- SD = 9.8 +/- 4 micrograms/d) (P less than 0.01). Because there is a strong relationship between E1 and PR (r = 0.64; P less than 0.001), CT secretory capacity appears to be modulated by estrogen circulating levels. This modulation leads to a menopause-related decrease in iCT. In osteoporotics, an independent impairment of CT production drastically lowers PR and basal iCT levels. CT might be one of the determining factors in the pathogenesis of postmenopausal osteoporosis. [less ▲]Detailed reference viewed: 6 (3 ULg)
Etude de la proliferation lymphocytaire humaine in vitro en reponse a l'anatoxine tetanique.
Lecart, Marie-Paule ; ; Heinen, Ernst et al
in Revue Médicale de Liège (1989), 44(13-14), 455-63Detailed reference viewed: 33 (1 ULg)
Thromboxane and prostacyclin release in adult respiratory distress syndrome
Deby, Ginette ; ; Lamy, Maurice et al
in Intensive Care Medicine (1987), 13Detailed reference viewed: 11 (2 ULg)